Greenstreet Yvonne, chief executive officer of Alnylam Pharmaceuticals (ALNY), has been a consistent seller of company stock over the past several months, with no open-market purchases recorded in her recent SEC Form 4 filings. Across 96 total transactions in ALNY, her cumulative sell value reached approximately $27.6 million, while her buy value stood at zero. The selling pattern is heavily concentrated in the first week of March 2026, when she executed 17 separate open-market sales between March 2 and March 4, ranging from roughly $41,000 to $545,000 per transaction. These sales totaled about $2.9 million in that three-day window alone, following a single large sale of $2.16 million on February 13, 2026.
The transaction mix also includes non-discretionary items that do not reflect active trading decisions. On March 2, 2026, Greenstreet received multiple stock awards valued at $0, and on February 27 she exercised options (code M) with no cash value reported. These are typical compensation-related events for an executive, distinct from her open-market sales, which are the only transactions showing a clear directional bias. Her most recent sale occurred on January 12, 2026, at $35,515, but the bulk of her activity has clustered in the last two weeks, suggesting an accelerated divestment phase.
Notably, Greenstreet has not engaged in any open-market purchases (code P) during the observed period, and her recent 20 transactions are entirely sales or compensation-related grants. The absence of buys, combined with the size and timing of her March sales, points to a sustained reduction in her ALNY holdings. While the filings do not indicate whether these sales were pre-scheduled under a Rule 10b5-1 plan, the pattern is unambiguous: Greenstreet is monetizing her equity position in Alnylam rather than accumulating more shares.
AI-assisted summary